Topics:

Melanoma

TERT Promoter Mutations Common in Melanoma

A recent study has confirmed that TERT promoter mutations are common genetic mutations in cutaneous melanoma, mutations that may be linked with poor prognosis.

Melanoma

Researchers have identified two new panRAF inhibitors that could be used to treat patients with BRAF- or NRAS-mutant melanoma, and those who have developed resistance to BRAF inhibitors.

Using whole-exome sequencing, researchers were able to define the genetic basis for deriving benefit from treatments that block CTLA-4 in melanoma.

The addition of sargramostim to the anti-CTLA-4 ipilimumab resulted in a significant improvement in overall survival in patients with metastatic melanoma.

In this interview we discuss a patient who experienced regression of BRAF-inhibitor-induced eruptive melanocytic nevi following concomitant addition of a MEK inhibitor.

Positive genetic risk information about melanoma may help to prompt people to discuss melanoma risk with a wider variety of family members, according to a new study.

A recent study has confirmed that TERT promoter mutations are common genetic mutations in cutaneous melanoma, mutations that may be linked with poor prognosis.

Treatment with a BRAF and MEK inhibitor resulted in modest clinical efficacy in patients whose melanoma had progressed after treatment with a BRAF inhibitor.

Pages

Subscribe to Melanoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.